Page last updated: 2024-11-11

trandolaprilat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trandolaprilat: RN given refers to cpd without isomeric designation; RN 87679-71-8 refers to trandolaprilat [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trandolaprilat : A heterobicyclic compound that is trandolapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of the prodrug trandolapril. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5464097
CHEMBL ID1201387
CHEBI ID141521
SCHEMBL ID197063
MeSH IDM0169475

Synonyms (45)

Synonym
x93 ,
trandolaprilat
ru-44403
CHEMBL1201387
(2s,3ar,7as)-1-[(2s)-2-[[(2s)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
trandolaprilate
87679-71-8
CHEBI:141521 ,
(2s,3ar,7as)-1-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid
1-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1h-indole-2-carboxylic acid
trandolapril diacid
trandolaprilatum
(2s,3ar,7as)-1-[(2s)-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid
unii-rr6866vl0o
trandolaprilate [inn-french]
trandolaprilat [inn]
trandolaprilatum [inn-latin]
ru 44403
rr6866vl0o ,
trandolapril diacid [mi]
trandolaprilat [who-dd]
trandolapril impurity e [ep impurity]
gtpl6455
SCHEMBL197063
AHYHTSYNOHNUSH-HXFGRODQSA-N
C21515
(2s,3ar,7as)-1-(2-((s)-1-carboxy-3-phenylpropylamino)propanoyl)octahydro-1h-indole-2-carboxylic acid
(2s,3ar,7as)-1-[(2s)-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid (non-preferred name)
(2s,3ar,7as)-1-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2s,3ar,7as)-1-(((s)-1-carboxy-3-phenylpropyl)-l-alanyl)octahydro-1h-indole-2-carboxylic acid
DB14209
Q27089019
ru44403
EX-A4862
(2s,3ar,7as)-1-((s)-2-(((s)-1-carboxy-3-phenylpropyl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
AC-36725
trandolapril impurity e
DTXSID101024709
CS-0014045
HY-A0116
trandolapril impurity e (ep impurity)
trandolaprilate (inn-french)
(2s,3ar,7as)-1-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
trandolaprilatum (inn-latin)
AKOS040744688

Research Excerpts

Actions

ExcerptReferenceRelevance
"1. Trandolaprilat was found to inhibit angiotensin I (Ang I)-induced contraction of the rat thoracic aorta, and to augment bradykinin(BK)-induced contraction of the guinea pig ileum. "( Pharmacological action of (-)-(2S,3aR,7aS)-1-[(S)-N-[(S)-1-carbonyl-3- phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolaprilat) in isolated smooth muscle preparations.
Fujikura, H; Hasegawa, Y; Ishii, Y; Sekiguchi, N; Takayanagi, I, 1993
)
1.11

Pharmacokinetics

ExcerptReferenceRelevance
" The peak plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were slightly higher in the older group, but the elimination half-life (t1/2) was the same, with no accumulation after repeat dosing."( Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension.
Arner, P; Bryce, T; Engfeldt, P; Lenfant, B; Mouren, M; Stepniewski, JP; Sultan, E; Wade, A, 1994
)
0.29
"1 mg/kg RU44403 was not dose proportional, suggesting nonlinear pharmacokinetic profile."( Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hasegawa, Y; Hirayama, M; Kurihara, A; Manabe, T,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction.
Kandikere, VN; Mudigonda, K; Nirogi, RV; Shrivastava, W, 2006
)
0.59

Dosage Studied

ExcerptRelevanceReference
" Orally dosed RU44403 was scarcely absorbed from the gastrointestinal tract (3% of dose), whereas its prodrug was found to be rapidly absorbed (32."( Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hasegawa, Y; Hirayama, M; Kurihara, A; Manabe, T,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
drug metabolitenull
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organic heterobicyclic compound
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Trandolapril Action Pathway34
Trandolapril Metabolism Pathway12

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345457Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))1994Journal of cardiovascular pharmacology, , Volume: 23 Suppl 4Compared properties of trandolapril, enalapril, and their diacid metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's14 (63.64)18.2507
2000's4 (18.18)29.6817
2010's2 (9.09)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.84 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.65 (4.65)
Search Engine Demand Index107.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (20.83%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other17 (70.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]